Department of Radiation Oncology, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA.
Future Oncol. 2013 May;9(5):737-45. doi: 10.2217/fon.13.19.
The purpose of this study was to describe the prognostic significance of ALDH7A1 in surgically treated non-small-cell lung carcinoma. (NSCLC).
MATERIALS & METHODS: We immunohistochemically analyzed ALDH7A1 expression in surgically resected NSCLC from 89 patients using a tissue microarray.
ALDH7A1 staining was positive in 43 patients and negative in 44 patients, with two tumor sections missing. For stage I NSCLC patients, ALDH7A1 positivity was associated with decreased recurrence-free and overall survival. Multivariate analysis demonstrated that ALDH7A1-expressing NSCLC tumors had a significantly higher incidence of lung cancer recurrence compared with patients with ALDH7A1-negative tumors, although there was no association with overall survival.
For patients with NSCLC, low ALDH7A1 expression was associated with a decreased incidence of cancer recurrence. Specifically in stage I patients, negative staining for ALDH7A1 was associated with improved recurrence-free and overall survival, suggesting a predictive role in surgically treated patients.
本研究旨在描述 ALDH7A1 在手术治疗非小细胞肺癌（NSCLC）中的预后意义。
我们使用组织微阵列对 89 例手术切除的 NSCLC 患者的 ALDH7A1 表达进行了免疫组织化学分析。
43 例患者的 ALDH7A1 染色阳性，44 例患者的 ALDH7A1 染色阴性，有两个肿瘤切片缺失。对于 I 期 NSCLC 患者，ALDH7A1 阳性与无复发生存和总生存时间缩短相关。多因素分析表明，与 ALDH7A1 阴性肿瘤患者相比，ALDH7A1 表达的 NSCLC 肿瘤患者肺癌复发的发生率显著更高，尽管与总生存时间无关。
对于 NSCLC 患者，ALDH7A1 低表达与癌症复发发生率降低相关。具体在 I 期患者中，ALDH7A1 阴性染色与无复发生存和总生存时间的改善相关，提示在手术治疗患者中有预测作用。
